Global and Local Pharmacovigilance Services, since 2008

Prabjot Hunjan joins Arriello
as Director of Global Drug Safety.

Missing image

Arriello welcomes another senior pharmacovigilance leader to our growing team of PV experts.

Prabjot joins Arriello’s Pharmacovigilance team with over 16 years of experience across both clinical trials and post-marketing within European and Global PV operations, both in CROs and pharma, and with six years in management.

His CRO & pharma experience includes director-level management, leading and developing the Pharmacovigilance function whilst delivering Pharmacovigilance Quality and Process Improvements.

Prabjot has also acted as EU QPPV and Deputy on behalf of Marketing Authorization Holders in the EU and has worked within a large team as a program and product lead on a well-established MS product. 

Prabjot is also a trained auditor and experienced in EU GDPR as a Data Protection Officer.

He will report to Arriello’s VP of Global Dug Safety @kieranodonnell

Latest news.

Webinar on designing stability studies for drugs & medical devices to get regulatory approval faster. Expert speaker, covers challenges & aligning commercial strategy.
Webinar: Stability study design for optimized regulatory approval
Under-utilized informal meetings with EMA and FDA offer valuable insights for drug development. Learn more...
Meeting EMA and FDA: Formal and Informal Pathways in Search of Alignment
Arriello Appoints Agile Project Management Expert Daithí O'Connor-Bray to Lead PMO. 25+ Years' Experience in Cross-Functional Collaboration & Process Optimization Across Pharma, Finance & Manufacturing.
Daithí O'Connor-Bray appointed as Director of PMO.